Skip to main content
padlock icon - secure page this page is secure

Aptamer (AS1411)-Conjugated Liposome for Enhanced Therapeutic Efficacy of miRNA-29b in Ovarian Cancer

Buy Article:

$106.73 + tax (Refund Policy)

AS1411 Aptamer-functionalized liposome was successfully formulated and found to be nanosized. Flow cytometer and CLSM results demonstrated that Aptamer enhanced the targeting of carrier in the cancer cells via nucleolin-mediated transmembrane endocytosis pathway. The lipofectaminebased miR-29b showed a typical concentration-dependent cytotoxic effect in the cancer cells. LP-miR induced a significant reduction in the cell viability of A2780 cells compared to that of nontreated control, while LP-Mut (mutant loaded) did not have any effect on the cell viability indicating the importance of the specific gene sequencing. LP-miR induced a significant decrease in the green fluorescence which is indicative of the decrease in the cell viability. Simultaneously, higher PI positive cells were observed for LP-miR treated cancer cells in Live/Dead assay. Cells treated with LP-miR exhibited the brightest fluorescence indicating the presence of apoptotic cells. Significant increase in the Annexin-V+ cells and PI+ cells were observed for cell treated with LP-miR compared to that of non-treated control indicating the potential of miR-29b. This novel miR-29b-loaded Aptamer-directed liposome could potential serve as a new platform to improve the therapeutic outcome in ovarian cancers.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Aptamer; Cancer Targeting; Cancer Targeting,miRNA; Liposomes; Ovarian Cancers

Document Type: Research Article

Affiliations: Tianjin Baodi Hospital, Tianjin 301800, China

Publication date: April 1, 2020

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more